Advertisement

Journal of NeuroVirology

, Volume 23, Issue 4, pp 637–637 | Cite as

Erratum to: Acyclovir resistance in herpes simplex virus type I encephalitis: a case report

  • M. Bergmann
  • R. Beer
  • M. Kofler
  • R. Helbok
  • B. Pfausler
  • E. SchmutzhardEmail author
Erratum
  • 637 Downloads

Erratum to: J. Neurovirol. (2017) 23:335–337

DOI 10.1007/s13365-016-0489-5

We apologize for the mistake which slipped through all careful reading and re-reading: it must, correctly, read throughout the entire paper ... foscarnet i.v. 60 mg per kg bodyweight (b.w.), t.i.d.

It is correct that 40 mg/kg b.w. is the recommended daily dose (Chilukuri and Rosen 2011), but in view of the dramatic clinical and neuro-imaging course we opted for an increased dose carefully monitoring for side effects.

References

  1. Bergmann M, Beer R, Kofler M, Helbok R, Pfausler B, Schmutzhard E (2017) Acyclovir resistance in herpes simplex virus type I encephalitis: a case report. J Neurovirol 23(2):335–337Google Scholar
  2. Chilukuri S, Rosen T (2003) Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 21:311–320CrossRefPubMedGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2017

Authors and Affiliations

  • M. Bergmann
    • 1
  • R. Beer
    • 1
  • M. Kofler
    • 1
  • R. Helbok
    • 1
  • B. Pfausler
    • 1
  • E. Schmutzhard
    • 1
    Email author
  1. 1.Department of Neurology, Neurocritical Care UnitMedical University InnsbruckInnsbruckAustria

Personalised recommendations